XDEMVY

Growth

lotilaner ophthalmic solution

NDAOPHTHALMICSOLUTION/DROPS

Approved

Jul 2023

Lifecycle

Growth

Competitive Pressure

0/100

Mechanism of Action

Pharmacologic Class:

Ectoparasiticide

Loss of Exclusivity

LOE Date

Dec 14, 2038

155 months away

Patent Expiry

Dec 14, 2038

Exclusivity Expiry

Jul 24, 2028

Patent Records (5)

Patent #	Expiry	Type	Use Code
8383659	Jan 17, 2030	SubstanceProduct	—
11197847	Dec 14, 2038		U-3674
11690826	Dec 14, 2038		U-3674
11690827	Dec 14, 2038		U-3674
10835517	Dec 14, 2038		U-3674

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers